Komandoor Srivathsan

Komandoor Srivathsan

Auto-generated profile, based on publicly available information

Komandoor Srivathsan

Department of Cardiovascular Medicine Mayo Clinic Phoenix Arizona USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JSJohn William Schleifer
John William Schleifer
FMFarouk Mookadam
Farouk Mookadam
EKEvan P. Kransdorf
Evan P. Kransdorf
UNUdai Nanda
Udai Nanda
JAJonathon C. Adams
Jonathon C. Adams
KSKomandoor Srivathsan
Komandoor Srivathsan

21 July 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
PRPattara Rattanawong
Pattara Rattanawong
WSWin Shen
Win Shen
HMHicham Z. El Masry
Hicham Z. El Masry
DSDan Sorajja
Dan Sorajja
KSKomandoor Srivathsan
Komandoor Srivathsan
LSLuis R. Scott
Luis R. Scott
Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID‐19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID‐19 treatments. Common unintended nontherapeutic target effects of COVID‐19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P‐glycoprotein inhibition. Drug‐drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID‐19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID‐19 patients with concomitant atrial fibrillation.

21 August 2024 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
ASAnil Sriramoju
Anil Sriramoju
SIShruti Krishna Iyengar
Shruti Krishna Iyengar
KSKomandoor Srivathsan
Komandoor Srivathsan
The landscape of cardiac pacemaker technology has undergone significant evolution over the last two decades, transitioning from simple single-chamber devices to sophisticated multi-chamber rate-responsive systems and cardioverter defibrillators. This progression has introduced a complex array of complications inherent to device implantation and operation, encompassing both mechanical and clinical challenges. These complications notably include lead dislodgment, device migration, venous thrombosis, and hemothorax, which not only affect patient outcomes but also impose substantial economic burdens. This review meticulously analyzes these complications, elucidating their mechanisms, clinical implications, and the economic consequences associated with their management. It also outlines current and emerging strategies aimed at mitigating these complications, emphasizing the need for continual updates in clinical practices and protocols. Through this discourse, the review seeks to equip clinicians with a comprehensive understanding of these complications, thereby enhancing the safety and efficacy of cardiac pacing interventions.

23 October 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
SIShruti Krishna Iyengar
Shruti Krishna Iyengar
SISumedh Iyengar
Sumedh Iyengar
KSKomandoor Srivathsan
Komandoor Srivathsan
For many years, guidelines have suggested thermal ablation for the treatment of atrial fibrillation. Thermal ablation involves the destruction of tissue, leading to multiple complications. This ablation technique has been tried and tested, however, newer techniques are being investigated in order to avoid these complications. Pulsed field ablation, a nonthermal method of tissue ablation, is being explored as a more safe and efficient way to treat atrial fibrillation. This mini review aims to highlight the mechanisms of pulsed field ablation, its history and evolution, previous studies showing its efficacy, its major challenges and pitfalls, and future advancements to overcome these challenges. This method of ablation could potentially revolutionize the treatment of atrial fibrillation and prevent recurrences, thereby making it easier for the physicians and patients involved.

24 November 2009 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
NBNisha L. Bhatia
Nisha L. Bhatia
JHJulie Humphries
Julie Humphries
KCKrishnaswamy Chandrasekaran
Krishnaswamy Chandrasekaran
KSKomandoor Srivathsan
Komandoor Srivathsan

29 October 2021 in Current Opinion in Cardiology
Verified
Journal Article
Closed access
NKNway Le Ko Ko
Nway Le Ko Ko
ASAnil Sriramoju
Anil Sriramoju
BKBanveet Kaur Khetarpal
Banveet Kaur Khetarpal
KSKomandoor Srivathsan
Komandoor Srivathsan
Purpose of review: Atrial flutter (AFL) is the second most prevalent arrhythmia after atrial fibrillation (AF). It is a macro-reentrant tachycardia that is either cavotricuspid isthmus dependent (typical) or independent (atypical). This review aims at highlighting mechanism, diagnosis and treatment of atypical AFL and the recent developments in electroanatomic mapping. Recent findings: Incidence of left AFL is at an exponential rise presently with increase in AF ablation rates. The mechanism of left AFL is most often peri-mitral, roof-dependent or within pulmonary veins in preablated, in contrast to posterior or anterior wall low voltage areas in ablation naïve patients. Linear lesions, compared to pulmonary vein isolation alone, have higher incidence of atypical right or left AFL. Catheter ablation for atypical AFL is associated with lower rates of thromboembolic events, transfusions, and length of stay compared to typical AFL. Summary: Advances in mapping have allowed rapid simultaneous acquisition of automatically annotated points in the atria and identification of details of macro-reentrant circuits, including zones of conduction block, scar, and slow conduction.